Cingulate
Update in progressCING (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Cingulate Inc. is a biopharmaceutical company using its drug-delivery platform to develop treatments for ADHD and anxiety in the United States. Its lead candidate, CTx-1301 (dexmethylphenidate), is in Phase 3 for ADHD in children, adolescents, and adults. CTx-2103 (buspirone) is in formulation development for anxiety. The company plans to begin a clinical program for CTx-1302 (dextroamphetamine) for ADHD. Founded 2012, based in Kansas City, Kansas.
Company score
- Sentiment
- 0.38
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.23
- Governance
- 0.17
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.24
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Shane J. Schaffer Pharm.D.
- Founded2012
- Employees14
- Websitewww.cingulate.com
Identifiers
- ISINUS17248W3034
- FIGIBBG012G40MY2
- CUSIP17248W105
- CIK0001862150